Regulatory Authority Actions

>

Latest News

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
FDA Accepts Breyanzi sBLA from Bristol Myers Squibb and Grants It Priority Review for MZL

August 6th 2025

Bristol Myers Squibb is seeking approval of Breyanzi (lisocabtagene maraleucel) to treat relapsed or refractory marginal zone lymphoma, making this the fifth cancer type for which the cell therapy would be approved.

Healthcare professional checks a digital checklist using advanced technology, emphasizing efficiency and accuracy in modern medical systems | Image Credit: © ACHJIMA - stock.adobe.com
Biocon’s Ustekinumab Biosimilar Gets MHRA Approval

May 29th 2025

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC

April 29th 2025

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com
CHMP Recommends Jazz Pharmaceuticals Therapy for Biliary Tract Cancer

April 25th 2025

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com
MHRA Approves GSK Therapy Combinations for Multiple Myeloma

April 21st 2025

Video Interviews

More News

© 2025 MJH Life Sciences

All rights reserved.